

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

07 Jul 2026

### A study to compare the relative bioavailability of Raha and GlaxoSmithKline formulations of bupropion 150 mg sustained-release tablets in 24 healthy adult volunteers under fasting conditions

#### Protocol summary

##### Study aim

The study aims to evaluate the bioequivalence of bupropion 150 mg extended-release tablets produced by two different pharmaceutical companies under fasting conditions

##### Design

This randomized, single-dose, two-way, crossover study is conducted to compare the pharmacokinetic of bupropion and Wellbutrin® tablets in 24 healthy adults volunteers. Volunteers will be sorted and receive a number from 1 to 24. In the first phase of the study, 12 volunteers will receive bupropion manufactured by Raha and the remaining 12 volunteers will receive Wellbutrin® produced by GlaxoSmithKline company. The administered drugs will be replaced by each other in the second phase of the study.

##### Settings and conduct

The dose administration and subsequent sample collection will be performed in S. Motahhari hospital (Gonbade Kavous, Iran).

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: 18-55 years of age. The subject is available for the entire study period and is willing to adhere to protocol requirements as evidenced by written informed consent. Good health at screening. Exclusion criteria: History of any drug hypersensitivity or intolerance. Significant history or current evidence of chronic disease. Receipt of any drug as part of a research study within 30 days prior to the present study.

##### Intervention groups

First intervention group: A single 150 mg oral dose of bupropion (1 tablet) manufactured by Raha company to 12 subjects. Second intervention group: A single 150 mg oral dose of Wellbutrin (1 tablet) manufactured by GlaxoSmithKline company to 12 subjects. Since in this study, the volunteers will receive both Test and Reference drugs, each volunteer will act as his own

control.

##### Main outcome variables

Drug plasma concentration; Area under the plasma concentration-time curve

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20130626013776N39**

Registration date: **2021-04-23, 1400/02/03**

Registration timing: **prospective**

Last update: **2021-04-23, 1400/02/03**

Update count: **0**

##### Registration date

2021-04-23, 1400/02/03

##### Registrant information

##### Name

Hossein Amini

##### Name of organization / entity

Golestan University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 17 1442 1651

##### Email address

hamini@sbmu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-06-21, 1400/03/31

##### Expected recruitment end date

2021-12-22, 1400/10/01

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

A study to compare the relative bioavailability of Raha and GlaxoSmithKline formulations of bupropion 150 mg sustained-release tablets in 24 healthy adult volunteers under fasting conditions

**Public title**

Bioequivalence study of bupropion 150 mg sustained-release tablets

**Purpose**

Basic science

**Inclusion/Exclusion criteria****Inclusion criteria:**

18-55 years of age The subject is able and willing to provide signed informed consent. The subject is available for the entire study period and is willing to adhere to protocol requirements as evidenced by written informed consent. The subject has stable residence and telephone. Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.

**Exclusion criteria:**

History of allergy or sensitivity to bupropion. History of any drug hypersensitivity or intolerance which, in the opinion of the investigator, would compromise the safety of the subject of the study. Significant history or current evidence of chronic infectious disease, system disorder or organ dysfunction. Presence of gastrointestinal disease or history of malabsorption within the last year. History of a medical disorders occurring within the last year that required hospitalization or medication. Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to dosing. Receipt of any drug as part of a research study within 30 days prior to the present study. Donation or significant loss of whole blood (480 ml or more) within 30 days prior to the present study.

**Age**

From **18 years** old to **55 years** old

**Gender**

Both

**Phase**

Bioequivalence

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **24**

More than 1 sample in each individual

Number of samples in each individual: **13**

A volume of 3 ml of blood is obtained in each sampling time through a venous cannula

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Each subject is identified by a number from 1 to 24. This

number is allocated according to their entrance to volunteers' list in the screening day. Then, the following randomization table is used according to the crossover design of the study. All participants randomized into two sequences of Test/Reference and Reference/Test products.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description****Placebo**

Not used

**Assignment**

Crossover

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Golestan University of Medical Sciences

**Street address**

Falsafi Building, Sari Road Km 2

**City**

Gorgan

**Province**

Golestan

**Postal code**

4934174515

**Approval date**

2021-01-24, 1399/11/05

**Ethics committee reference number**

IR.GOUMS.REC.1400.001

**Health conditions studied****1****Description of health condition studied****ICD-10 code****ICD-10 code description****Primary outcomes****1****Description**

Drug plasma concentration

**Timepoint**

At time zero and 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24 and 48 h after drug administration

**Method of measurement**

Blood sampling and measurement of drug concentrations by high-performance liquid chromatography

## 2

### **Description**

Area under plasma concentration-time curve

### **Timepoint**

At time zero and 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24 and 48 h after drug administration

### **Method of measurement**

Blood sampling and measurement of drug concentrations by high-performance liquid chromatography

## **Secondary outcomes**

### 1

#### **Description**

Plasma half-life

#### **Timepoint**

From the terminal 40 hours of plasma concentration-time profile

#### **Method of measurement**

Blood sampling and drug analysis by high-performance liquid chromatography method

## **Intervention groups**

### 1

#### **Description**

Intervention group: Oral administration of a single 150 mg dose of bupropion (1 tablet) manufactured by Raha to healthy volunteers under fasting condition in the morning of the experiment day

#### **Category**

Treatment - Drugs

### 2

#### **Description**

Intervention group: Oral administration of a single 150 mg dose of Wellburin (1 tablet) manufactured by GlaxoSmithKline to healthy volunteers under fasting condition in the morning of the experiment day

#### **Category**

Treatment - Drugs

## **Recruitment centers**

### 1

#### **Recruitment center**

##### **Name of recruitment center**

Dialysis Center, S. Motahhari Hospital

##### **Full name of responsible person**

Yahya Naserifard

##### **Street address**

Taleghani Street

##### **City**

Gonbade Kavous

##### **Province**

Golestan

##### **Postal code**

4916817693

##### **Phone**

+98 17 3252 5972

##### **Fax**

+98 17 3252 5972

##### **Email**

haminhplc@yahoo.com

## **Sponsors / Funding sources**

### 1

#### **Sponsor**

##### **Name of organization / entity**

Raha Pharmaceuticals

##### **Full name of responsible person**

Dr. Akram Sharifian

##### **Street address**

Central Office: No.11, Sofeh Ind. Zone, 7th km of Shiraz Road

##### **City**

isfehan

##### **Province**

Isfehan

##### **Postal code**

81745-567

##### **Phone**

+98 31 3654 0659

##### **Fax**

+98 31 3654 0183

##### **Email**

info@rahapharma.com

##### **Web page address**

<http://rahapharm.com/home>

##### **Grant name**

Bioequivalence Study of Bupropion

##### **Grant code / Reference number**

##### **Is the source of funding the same sponsor organization/entity?**

No

##### **Title of funding source**

Raha Pharmaceuticals

##### **Proportion provided by this source**

100

##### **Public or private sector**

Private

##### **Domestic or foreign origin**

Domestic

##### **Category of foreign source of funding**

*empty*

##### **Country of origin**

##### **Type of organization providing the funding**

Industry

## **Person responsible for general inquiries**

#### **Contact**

##### **Name of organization / entity**

Gorgan University of Medical Sciences

##### **Full name of responsible person**

Hosseini Amini

##### **Position**

Associate professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Sari Road, Km 2

**City**

Gorgan

**Province**

Golestan

**Postal code**

4934174515

**Phone**

+98 17 3252 5972

**Fax**

+98 17 3252 5972

**Email**

haminhplc@yahoo.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Gorgan University of Medical Sciences

**Full name of responsible person**

Hossein Amini

**Position**

Associate professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Sari Road, Km 2

**City**

Gorgan

**Province**

Golestan

**Postal code**

4934174515

**Phone**

+98 17 3252 5972

**Fax**

+98 17 3252 5972

**Email**

haminhplc@yahoo.com

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Gorgan University of Medical Sciences

**Full name of responsible person**

Hossein Amini

**Position**

Associate professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Sari Road, Km 2

**City**

Gorgan

**Province**

Golestan

**Postal code**

4934174515

**Phone**

+98 17 3252 5972

**Fax**

+98 17 3252 5972

**Email**

haminhplc@yahoo.com

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

Data are confidential and need permission from the company.

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available